Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Current assets:
Cash in escrow
Cash
Prepaid expenses
Other receivables
Total current assets
Cash and investments held in trust account
TOTAL ASSETS
Current liabilities:
Common stock redemption liabilities
Accrued liabilities
Other payable – related party
Income tax payable
Note payable – related party
Amount due to a related party
Total current liabilities
Deferred underwriting compensation
Deferred underwriting compensation
Deferred underwriting compensation
TOTAL LIABILITIES
Temporary equity:
Common stock, subject to possible redemption: 176,562 and 279,990 shares (at redemption value of $12.73 and $10.86 per share, respectively)
Stockholders’ deficit:
Common stock, $0.0001 par value; 26,000,000 shares authorized; 2,637,500 shares issued and outstanding (excluding 176,562 and 279,990 shares, subject to possible redemption, respectively)
Accumulated deficit
Total stockholders’ deficit
TOTAL LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ DEFICIT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support